ScholarIQanswers from OpenAlex

Systemic Delivery of Monoclonal Antibodies to the Central Nervous System for Brain Tumor Therapy

PaperCitations, authors & open-access status

Systemic Delivery of Monoclonal Antibodies to the Central Nervous System for Brain Tumor Therapy is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Systemic Delivery of Monoclonal Antibodies to the Central Nervous System for Brain Tumor Therapy have?

ScholarIQcitation count

Systemic Delivery of Monoclonal Antibodies to the Central Nervous System for Brain Tumor Therapy has 150 citations in the OpenAlex counts ScholarIQ stores.

When was Systemic Delivery of Monoclonal Antibodies to the Central Nervous System for Brain Tumor Therapy published?

ScholarIQyear

Systemic Delivery of Monoclonal Antibodies to the Central Nervous System for Brain Tumor Therapy has 2019 year in the ScholarIQ index.

What is the open-access status of Systemic Delivery of Monoclonal Antibodies to the Central Nervous System for Brain Tumor Therapy?

ScholarIQoa status

Systemic Delivery of Monoclonal Antibodies to the Central Nervous System for Brain Tumor Therapy has closed oa status in the ScholarIQ index.

What is the DOI of Systemic Delivery of Monoclonal Antibodies to the Central Nervous System for Brain Tumor Therapy?

ScholarIQdoi

The DOI for Systemic Delivery of Monoclonal Antibodies to the Central Nervous System for Brain Tumor Therapy is on the source record.

What is the PMID of Systemic Delivery of Monoclonal Antibodies to the Central Nervous System for Brain Tumor Therapy?

ScholarIQpmid

The PMID for Systemic Delivery of Monoclonal Antibodies to the Central Nervous System for Brain Tumor Therapy is on the source record.

What is the OpenAlex record for Systemic Delivery of Monoclonal Antibodies to the Central Nervous System for Brain Tumor Therapy?

ScholarIQopenalex

The OpenAlex for Systemic Delivery of Monoclonal Antibodies to the Central Nervous System for Brain Tumor Therapy is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial